Danske Regioner Report issue

Government Phase 3

Organization Overview

First Clinical Trial
2021
NCT04688788
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Danske Regioner

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Multiple Sclerosis (Phase 3)

Multiple Sclerosis, Chronic Progressive (Phase 3)

Multiple Sclerosis, Relapsing-Remitting (Phase 3)

Sclerosis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 5